YOLFTbeta
Daehan New Pharm Co. Ltd

Daehan New Pharm Co. Ltd

054670 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

5,030.00KRW-10.00 (-0.20%)

Price History

Full chart

Market Stats

Previous Close5,040.00
Open5,020.00
Day Range5,010.00 – 5,190.00
52-Week Range5,030.00 – 7,900.00
Volume5.63K
Market Cap78.32B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield1.81%
Beta0.16
50-Day Avg5,617.80
200-Day Avg6,270.75

About

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products. The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025. Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Wonseok Lee
  • Employees0
  • Headquarters66 Pharmaceutical Complex 1-gil, Hwaseong-si, South Korea, 18622, Korea
  • Websitehttps://www.dhnp.co.kr

Leadership

  • Mr. Wonseok LeeCEO & Executive Director
  • Mr. Jeong-Su ChoiExecutive Director & Head of Finance Department · b. 1967
  • Mr. Sang-Ho ParkExecutive Director & Head of Business Management Division · b. 1967
  • Mr. Dong-Hoon YangExecutive Director & Head of New Business Division · b. 1968
  • Mr. YeongDong KimExecutive Director & Head of Overseas Business Division · b. 1969
  • Mr. SeongGil MaExecutive Director & Head of Management Innovation Division · b. 1971
  • Mr. GwangHo ChoDirector & Head of Pharmaceutical Business Division · b. 1978
  • Mr. JongSeong KimExecutive Director & Head of Pharmaceutical Business Division · b. 1968
  • Mr. SeongUn ChoExecutive Director & Head of Academic Development Division · b. 1964

Financials

Income Statement

Currency: KRW2009-12-312010-12-312011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----71.94B90.23B109.40B130.82B119.53B134.10B149.51B166.59B197.96B204.22B202.19B202.40B
Growth (%)-----+25.42%+21.25%+19.57%-8.63%+12.19%+11.50%+11.42%+18.83%+3.16%-1.00%+0.11%
Cost of Revenue----32.97B39.44B48.46B60.84B56.37B61.75B72.95B82.62B107.41B110.24B105.31B110.14B
Gross Profit----38.97B50.79B60.94B69.98B63.16B72.35B76.56B83.97B90.55B93.98B96.88B92.26B
Gross Margin----54.17%56.29%55.71%53.49%52.84%53.95%51.21%50.41%45.74%46.02%47.92%45.58%
Operating Expense----32.04B40.76B60.70B58.62B43.23B51.65B85.83B58.85B54.06B75.17B78.22B80.54B
Operating Income----6.93B10.03B244.51M11.36B19.94B20.70B-9.27B25.12B36.48B18.81B18.67B11.72B
Operating Margin----9.64%11.12%0.22%8.68%16.68%15.44%-6.20%15.08%18.43%9.21%9.23%5.79%
EBITDA------------39.00B25.93B24.23B20.96B
EBITDA Margin------------19.70%12.69%11.99%10.35%
Net Income----2.66B4.15B-5.67B-20.58B2.45B15.24B-9.93B15.69B24.32B12.54B15.47B15.26B
Net Income Margin----3.70%4.60%-5.18%-15.73%2.05%11.36%-6.64%9.42%12.28%6.14%7.65%7.54%
R&D----91.24M184.91M327.43M450.26M-1.28B1.81B2.16B2.28B4.11B1.33B7.50B
R&D as % of Total Revenue----0.13%0.20%0.30%0.34%-0.96%1.21%1.29%1.15%2.01%0.66%3.70%
Interest Expense----000001.42B1.01B907.33M1.25B1.76B1.76B1.67B
Interest Expense % of Total Revenue----0.00%0.00%0.00%0.00%0.00%1.06%0.68%0.54%0.63%0.86%0.87%0.83%

Balance Sheet

Currency: KRW2009-12-312010-12-312011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets----130.47B132.63B130.72B121.82B108.74B127.91B133.08B157.64B169.36B176.93B221.29B271.18B
Total Liabilities----56.58B55.43B59.52B70.09B65.66B66.84B75.95B75.18B66.40B67.57B95.85B131.24B
Total Equity----73.89B77.20B71.20B51.72B43.08B61.07B57.13B82.47B102.96B109.36B125.44B139.95B
Cash----784.93M1.86B8.17B4.29B7.99B17.22B15.37B97.00K524.00K202.00K29.73B19.97B
Total Debt------32.98B36.81B31.28B25.78B35.96B-----
Net Debt----------22.83B20.84B14.83B16.47B28.76B78.00B

Cash Flow

Currency: KRW2009-12-312010-12-312011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.30B-9.58B3.42B256.82M10.02B7.80B8.75B-2.42B20.47B22.89B13.55B16.58B14.25B12.57B18.95B5.06B
Investing Cash Flow10.10B-2.43B-2.80B-6.84B-4.94B-4.29B-1.53B-469.80M-11.77B-9.11B-16.79B-13.92B-6.93B-12.30B-29.12B-
Financing Cash Flow-7.01B11.28B-635.92M6.81B-4.69B-2.38B-930.41M-610.25M-5.07B-4.55B1.39B-2.72B-1.38B-2.23B20.51B-
Capital Expenditure2.00B1.71B1.20B1.24B6.69B3.86B4.57B1.25B1.73B9.08B9.46B10.55B3.51B9.93B34.26B51.07B
Free Cash Flow---------10.18B3.74B5.90B10.73B2.50B-15.34B-46.01B
Dividends Paid----701.76M701.76M701.76M701.76M----1.12B1.40B1.40B1.40B
FCF to OCF---------44.47%27.61%35.59%75.25%19.88%-80.96%-909.02%
Dividend Paid to FCF------------10.47%56.17%-9.15%-3.05%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Nov 13, 2016Feb 28, 2017May 14, 2017Aug 11, 2017Nov 14, 2017Feb 28, 2018May 15, 2018Aug 14, 2018Nov 13, 2018Feb 22, 2019Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual110.9814.474.87-103.0043.0258.3529.35-335.3531.15-10.7821.376.3414.22-78.913.89-360.9820.5734.174.59-193.3061.3046.6698.21-16.5490.6297.5264.7914.1595.90113.5056.32-669.79120.33-1244.22162.67-505.14210.55-485.05316.11135.25227.24245.78223.26389.87258.91273.28-82.79-1156.66283.53332.75365.80118.01827.40233.29422.49249.40315.25457.98354.71-234.34371.74398.95140.22191.17183.68214.30185.87503.23213.59802.52
Surprise----------------------------------------------------------------------
Timing------------------------------After-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market------------------------------

Key Statistics & Ratios

Market Cap78.32B
Enterprise Value139.40B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.37
Price / Book0.51
Revenue (TTM)211.48B
Gross Profit (TTM)88.94B
EBITDA14.48B
Profit Margin11.32%
Operating Margin3.84%
Return on Equity17.36%
Return on Assets2.35%
Shares Outstanding14.04M
Shares Float8.15M
Beta0.16
Dividend Yield1.81%
Dividend Rate100.00
Payout Ratio5.86%

Dividends

20251×
100.00Dec 29, 2025
20241×
100.00Dec 27, 2024
20231×
100.00Dec 27, 2023
20221×
100.00Dec 28, 2022
20211×
80.00Dec 29, 2021
20161×
50.00Dec 28, 2016
20061×
50.00Dec 27, 2006
20051×
50.00Dec 28, 2005
20041×
48.09Dec 29, 2004
20031×
48.09Dec 29, 2003
20021×
48.09Dec 27, 2002

Stock Splits

  • Nov 28, 2005602:579